Loading
Vitrolife AB Stock: price and insider trades · Sweden
No insider purchase over the last 90 days. The latest was filed 06 Feb 2026.
Vitrolife AB: what insiders have been doing
Headquartered in Gothenburg, Sweden, Vitrolife AB belongs to the Health Care sector and traces its origins to 1994. Filings by its managers are published through Finansinspektionen. 3 insiders have disclosed 3 filings since 18 October 2025.
No insider sold shares on the market over the period. Instead, the filings list 3 purchases totalling €98k, made by 3 insiders. Unlike grants, an open-market purchase is paid for by the insider, at the market price. The largest single trade was a purchase of €54k by Ermanno Sironi, published on 6 February 2026, equal to 0.0048% of the market capitalisation. Among those who bought: 1 finance chief, 1 senior executive and 1 chief executive.
Across the 890 companies tracked on its exchange, the median is 7 filings; at 3 filings, this issuer sits below that mark. The full history, which starts in 2026, counts 3 purchases against no sales.
The data flag 2 purchases as part of a group of insiders buying within 30 days of each other. Purchases made close together by different insiders form what is called a cluster. The most recent open-market purchase was published on 6 February 2026, 254 days ago. Most trades are made public on the day they happen. Under the Market Abuse Regulation, managers have three business days to notify their trades.
Other companies in the same sector with recent insider buying flagged by our signals: Anixa Biosciences Inc and Vivos Inc. Source: insider filings from Finansinspektionen. Past trades are no guide to future returns.
Key facts
Headquarters: Gothenburg, Sweden · Founded: 1994
Source: Wikidata (CC0).
Insider Decl.
3
Thresholds
n/a
Buy Volume
€98,038
3 ops. · all time
Sell Volume
n/a
n/a
Who traded when
BuySaleBronwyn Brophy O'Connor1 buy
Ermanno Sironi1 buy
Pär Svensson Ihrskog1 buy
Since the insiders bought
- +9.8%Entry SEK 89.35 · Close 16 Oct 2026 SEK 98.15
- +9.8%Entry SEK 89.35 · Close 16 Oct 2026 SEK 98.15
- +9.4%Entry SEK 89.70 · Close 16 Oct 2026 SEK 98.15
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
Fundamental score
Ranked 17,347 of 24,148 companies
37.0
score / 100
Value32
Quality42
FCF yld3.1%
Earn yld-40%
EV/EBITDA·
ROE-47%
Gross mgn58%
Net mgn·
Debt/EBITDA·
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Financial data
as of FY 2025FY ended December 2025 · cache
SEK 92.40
Analyst consensus
5 analysts1.50/5
SEK 95.00Target SEK 129.60(+40%)SEK 155.00
Income statement
RevenueSEK 3.4B
Gross profitSEK 2B58% margin
EBITDA-SEK 4.4B-128% margin
Net income-SEK 5B-147.0% margin
Valuation
PER (forward)17.6x
P/Book1.5x
Beta1.71
Balance sheet & cash
Market capSEK 12.5B
Total debtSEK 1.6B
Free Cash FlowSEK 388M
Debt / Equity20%
Profitability & ownership
ROE-46.5%
ROA2.8%
% insiders29.7%
% institutions59.4%
Last declaration on 6 February 2026
Declarations3 total
3,013 shares@ SEK 89.550.0022% mcap100.0% of flowAktieISIN SE0011205202FI:A003V712-1
Canonical exit: 7 May 2026 (T+90)
6,470 shares@ SEK 89.280.0048% mcap100.0% of flowAktieISIN SE0011205202FI:A003V709-1
Canonical exit: 7 May 2026 (T+90)
2,200 shares@ SEK 89.550.0017% mcap100.0% of flowAktieISIN SE0011205202FI:A003V642-1
Canonical exit: 5 May 2026 (T+90)
3 of 3 declarations
About Vitrolife AB
Vitrolife AB is a company in the healthcare and pharmaceutical sector, providing solutions for fertility and embryonic development. It is listed on the XSTO stock exchange.
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations
